Finance

October 2nd 2024

New facilities are expected to focus on manufacturing next-generation medicines and biologic medicines.

October 1st 2024

CN201 is currently being evaluated in Phase I and Phase Ib/II clinical trials for relapsed or refractory non-Hodgkin lymphoma and B-cell acute lymphocytic leukemia.

October 1st 2024

Partnership is expected to leverage Amneal’s global manufacturing and product development experience and Metsera’s portfolio of ultra-long acting injectables and oral nutrient-stimulated hormone analogs.

September 17th 2024

With a likely rate cut by the Federal Reserve this week, investors could rotate aggressively back to the sector.